**Supplementary Figure 1. Flow chart showing the identification of subjects.**



**Supplementary Figure 2. Kaplan–Meier curves for type 2 diabetes according to the group**

(a) All subjects; (b) 18–39 years; (c) 40–64 years; (d) ≥65 years



**Supplementary Table 1. Hazard ratios and 95% confidence intervals** **of antidepressant classes on type 2 diabetes compared to healthy controls**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Subjects**  **(n)** | **Events (n)** | **Follow-up duration (person-year)** | **Incidence rate**  **(per 1000 person-years)** | **Hazard ratio (95% Confidence interval)** | | | |
| **Crude** | **Model 1a** | **Model 2b** | **Model 3c** |
| Healthy controls | 276,048 | 24,577 | 3,954,318 | 6.2 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| SSRI | 188,456 | 7,557 | 1,542,828 | 4.9 | 0.88 (0.86–0.91)\*\*\* | 0.87 (0.85–0.90)\*\*\* | 0.88 (0.85–0.90)\*\*\* | 0.76 (0.73–0.79)\*\*\* |
| SNRI | 46,991 | 2,039 | 422,692 | 4.8 | 0.85 (0.81–0.89)\*\*\* | 0.72 (0.69–0.75)\*\*\* | 0.69 (0.66–0.73)\*\*\* | 0.60 (0.56–0.64)\*\*\* |
| TCA | 151,588 | 10,907 | 1,483,952 | 7.3 | 1.29 (1.26–1.32)\*\*\* | 1.06 (1.03–1.08)\*\*\* | 0.91 (0.88–0.93)\*\*\* | 0.82 (0.79–0.85)\*\*\* |
| MAOI | 316 | 30 | 3,355 | 8.9 | 1.54 (1.07–2.19)\* | 0.62 (0.43–0.89)\*\* | 0.50 (0.35–0.73)\*\* | 0.45 (0.31–0.65)\*\*\* |
| Others | 90,009 | 4,170 | 749,392 | 5.6 | 0.99 (0.95–1.02) | 0.86 (0.83–0.89)\*\*\* | 0.83 (0.80–0.86)\*\*\* | 0.67 (0.64–0.71)\*\*\* |

SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; MAOI, monoamine oxidase inhibitor

**a**Adjusted for age (years) and sex

**b**Adjusted for age (years), sex, and Charlson comorbidity Index

**c**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, and zolpidem use

\**P* <0.05, \*\**P* <0.01, \*\*\**P* <0.001

**Supplementary Table 2. Hazard ratios and 95% confidence intervals of antidepressant classes on type 2 diabetes compared to DEP without antidepressants group.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Subjects**  **(n)** | **Events (n)** | **Follow-up duration (person-year)** | **Incidence rate**  **(per 1000 person-years)** | **Hazard ratio (95% Confidence interval)** | | | |
| **Crude** | **Model 1a** | **Model 2b** | **Model 3c** |
| DEP without antidepressants | 79,119 | 2,898 | 603,168 | 4.8 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| SSRI | 188,456 | 7,557 | 1,542,828 | 4.9 | 1.02 (0.97–1.06) | 0.98 (0.93–1.02) | 0.97 (0.93–1.02) | 0.94 (0.90–0.98)\*\* |
| SNRI | 46,991 | 2,039 | 422,692 | 4.8 | 0.97 (0.92–1.03) | 0.82 (0.78–0.87)\*\*\* | 0.81 (0.76–0.86)\*\*\* | 0.78 (0.74–0.83)\*\*\* |
| TCA | 151,588 | 10,907 | 1,483,952 | 7.3 | 1.48 (1.42–1.55)\*\*\* | 1.23 (1.18–1.28)\*\*\* | 1.11 (1.06–1.16)\*\*\* | 1.09 (1.05–1.14)\*\*\* |
| MAOI | 316 | 30 | 3,355 | 8.9 | 1.76 (1.23–2.53)\*\* | 0.79 (0.55–1.13) | 0.78 (0.54–1.12) | 0.80 (0.56–1.16) |
| Others | 90,009 | 4,170 | 749,392 | 5.6 | 1.14 (1.08–1.19)\*\*\* | 0.99 (0.94–1.03) | 0.96 (0.92–1.01) | 0.90 (0.85–0.94)\*\*\* |

DEP, depression; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; MAOI, monoamine oxidase inhibitor

**a**Adjusted for age (years) and sex

**b**Adjusted for age (years), sex, and Charlson comorbidity Index

**c**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, and zolpidem use

\**P* <0.05, \*\**P* <0.01, \*\*\**P* <0.001

**Supplementary Table 3. Hazard ratios and 95% confidence intervals of use of antidepressants on type 2 diabetes compared to healthy controls**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Subjects**  **(n)** | **Events (n)** | **Follow-up duration (person-year)** | **Incidence rate**  **(per 1000 person-years)** | **Hazard ratio (95% Confidence interval)** | | | |
|  | **Crude** | **Model 1a** | **Model 2b** | **Model 3c** |
| Healthy controls | | 276,048 | 24,577 | 3,954,318 | 6.2 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| SSRI | |  |  |  |  |  |  |  |  |
|  | Escitalopram | 113,437 | 3,762 | 870,521 | 4.3 | 0.78 (0.75–0.81)\*\*\* | 0.75 (0.72–0.77)\*\*\* | 0.73 (0.70–0.76)\*\*\* | 0.63 (0.59–0.66)\*\*\* |
|  | Fluoxetine | 36,605 | 1,265 | 318,606 | 4.0 | 0.70 (0.66–0.74)\*\*\* | 0.91 (0.86–0.97)\*\* | 0.88 (0.83–0.93)\*\*\* | 0.78 (0.73–0.84)\*\*\* |
|  | Fluvoxamine | 10,165 | 540 | 109,441 | 4.9 | 0.85 (0.78–0.92)\*\* | 0.85 (0.78–0.93)\*\*\* | 0.77 (0.70–0.85)\*\*\* | 0.68 (0.61–0.76)\*\*\* |
|  | Sertraline | 47,174 | 2,149 | 434,648 | 4.9 | 0.86 (0.83–0.90)\*\*\* | 0.85 (0.81–0.88)\*\*\* | 0.84 (0.80–0.88)\*\*\* | 0.74 (0.69–0.79)\*\*\* |
|  | Paroxetine | 50,753 | 2,495 | 491,563 | 5.1 | 0.89 (0.85–0.92)\*\*\* | 0.89 (0.85–0.92)\*\*\* | 0.86 (0.82–0.90)\*\*\* | 0.76 (0.71–0.81)\*\*\* |
| SNRI | |  |  |  |  |  |  |  |  |
|  | Duloxetine | 21,341 | 836 | 190,708 | 4.4 | 0.77 (0.72–0.82)\*\*\* | 0.56 (0.53–0.60)\*\*\* | 0.52 (0.48–0.56)\*\*\* | 0.45 (0.41–0.50)\*\*\* |
|  | Venlafaxine | 19,774 | 852 | 181,724 | 4.7 | 0.82 (0.76–0.87)\*\*\* | 0.83 (0.78–0.89)\*\*\* | 0.78 (0.73–0.84)\*\*\* | 0.68 (0.62–0.74)\*\*\* |
|  | Desvenlafaxine | 2,847 | 30 | 16,584 | 1.8 | 0.32 (0.22–0.45)\*\*\* | 0.35 (0.24–0.49)\*\*\* | 0.28 (0.20–0.41)\*\*\* | 0.24 (0.16–0.35)\*\*\* |
|  | Milnacipran | 9,514 | 578 | 99,676 | 5.8 | 1.00 (0.92–1.09) | 0.82 (0.75–0.89)\*\*\* | 0.73 (0.66–0.80)\*\*\* | 0.64 (0.57–0.71)\*\*\* |
| TCA | |  |  |  |  |  |  |  |  |
|  | Nortriptyline | 49,428 | 3,038 | 495,514 | 6.1 | 1.07 (1.03–1.11)\*\* | 0.85 (0.81–0.88)\*\*\* | 0.75 (0.71–0.78)\*\*\* | 0.68 (0.64–0.72)\*\*\* |
|  | Clomipramine | 5,543 | 351 | 57,682 | 6.1 | 1.05 (0.94–1.16) | 1.09 (0.98–1.21) | 0.99 (0.88–1.10) | 0.86 (0.76–0.98)\* |
|  | Amitriptyline | 109,334 | 8,482 | 1,108,600 | 7.7 | 1.33 (1.30–1.37)\*\*\* | 1.03 (1.01–1.06)\* | 0.88 (0.85–0.91)\*\*\* | 0.79 (0.76–0.83)\*\*\* |
|  | Imipramine | 36,367 | 2,489 | 377,730 | 6.6 | 1.14 (1.09–1.19)\*\*\* | 1.00 (0.95–1.04) | 0.91 (0.87–0.96)\*\*\* | 0.82 (0.77–0.87)\*\*\* |
| MAOI | |  |  |  |  |  |  |  |  |
|  | Selegiline | 316 | 30 | 3,355 | 8.9 | 1.54 (1.07–2.19)\* | 0.62 (0.43–0.89)\*\* | 0.50 (0.35–0.73)\*\*\* | 0.45 (0.31–0.65)\*\*\* |
| Others | |  |  |  |  |  |  |  |  |
|  | Mirtazapine | 18,590 | 1,018 | 173,939 | 5.9 | 1.02 (0.95–1.08) | 0.80 (0.75–0.85)\*\*\* | 0.77 (0.72–0.83)\*\*\* | 0.63 (0.58–0.69)\*\*\* |
|  | Bupropion | 14,203 | 458 | 110,474 | 4.1 | 0.73 (0.67–0.80)\*\*\* | 0.77 (0.70–0.85)\*\*\* | 0.73 (0.66–0.80)\*\*\* | 0.62 (0.55–0.70)\*\*\* |
|  | Trazodone | 67,548 | 3,282 | 580,751 | 5.7 | 1.00 (0.96–1.03) | 0.87 (0.84–0.90)\*\*\* | 0.81 (0.78–0.85)\*\*\* | 0.67 (0.63–0.71)\*\*\* |
|  | Vortioxetine | 7,697 | 57 | 41,852 | 1.4 | 0.24 (0.18–0.31)\*\*\* | 0.24 (0.18–0.31)\*\*\* | 0.20 (0.16–0.27)\*\*\* | 0.17 (0.13–0.22)\*\*\* |

SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; MAOI, monoamine oxidase inhibitor

**a**Adjusted for age (years) and sex

**b**Adjusted for age (years), sex, and Charlson comorbidity Index

**c**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, and zolpidem use

\**P* <0.05, \*\**P* <0.01, \*\*\**P* <0.001

**Supplementary Table 4. Hazard ratios and 95% confidence intervals of use of antidepressants on type 2 diabetes compared to DEP without antidepressants group.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Subjects**  **(n)** | **Events (n)** | **Follow-up duration (person-year)** | **Incidence rate**  **(per 1000 person-years)** | **Hazard ratio (95% Confidence interval)** | | | |
|  | **Crude** | **Model 1a** | **Model 2b** | **Model 3c** |
| DEP without antidepressants | | 79,119 | 2,898 | 603,168 | 4.8 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| SSRI | |  |  |  |  |  |  |  |  |
|  | Escitalopram | 113,437 | 3,762 | 870,521 | 4.3 | 0.92 (0.88–0.97)\*\*\* | 0.85 (0.81–0.90)\*\*\* | 0.84 (0.80–0.89)\*\*\* | 0.81 (0.77–0.85)\*\*\* |
|  | Fluoxetine | 36,605 | 1,265 | 318,606 | 4.0 | 0.81 (0.76–0.87)\*\*\* | 0.98 (0.92–1.05) | 0.98 (0.91–1.05) | 0.96 (0.90–1.03) |
|  | Fluvoxamine | 10,165 | 540 | 109,441 | 4.9 | 0.98 (0.89–1.07) | 0.94 (0.86–1.04) | 0.92 (0.84–1.02) | 0.92 (0.83–1.01) |
|  | Sertraline | 47,174 | 2,149 | 434,648 | 4.9 | 1.00 (0.94–1.05) | 0.94 (0.89–1.00)\* | 0.95 (0.89–1.00) | 0.92 (0.87–0.97)\*\* |
|  | Paroxetine | 50,753 | 2,495 | 491,563 | 5.1 | 1.02 (0.96–1.07) | 0.98 (0.92–1.03) | 0.97 (0.92–1.02) | 0.94 (0.89–1.00)\* |
| SNRI | |  |  |  |  |  |  |  |  |
|  | Duloxetine | 21,341 | 836 | 190,708 | 4.4 | 0.89 (0.82–0.96)\*\* | 0.67 (0.62–0.72)\*\*\* | 0.65 (0.60–0.71)\*\*\* | 0.64 (0.59–0.70)\*\*\* |
|  | Venlafaxine | 19,774 | 852 | 181,724 | 4.7 | 0.95 (0.88–1.02) | 0.92 (0.85–0.99)\* | 0.91 (0.84–0.99)\* | 0.89 (0.82–0.96)\*\* |
|  | Desvenlafaxine | 2,847 | 30 | 16,584 | 1.8 | 0.38 (0.26–0.54)\*\*\* | 0.39 (0.27–0.56)\*\*\* | 0.38 (0.27–0.55)\*\*\* | 0.38 (0.26–0.55)\*\*\* |
|  | Milnacipran | 9,514 | 578 | 99,676 | 5.8 | 1.15 (1.05–1.26)\*\* | 0.94 (0.86–1.03) | 0.92 (0.83–1.00) | 0.91 (0.83–1.00)\* |
| TCA | |  |  |  |  |  |  |  |  |
|  | Nortriptyline | 49,428 | 3,038 | 495,514 | 6.1 | 1.22 (1.16–1.28)\*\*\* | 0.98 (0.93–1.03) | 0.91 (0.86–0.96)\*\*\* | 0.90 (0.85–0.95)\*\*\* |
|  | Clomipramine | 5,543 | 351 | 57,682 | 6.1 | 1.21 (1.09–1.36)\*\*\* | 1.19 (1.07–1.33)\*\* | 1.17 (1.05–1.31)\*\* | 1.13 (1.01–1.26)\* |
|  | Amitriptyline | 109,334 | 8,482 | 1,108,600 | 7.7 | 1.53 (1.47–1.60)\*\*\* | 1.21 (1.16–1.26)\*\*\* | 1.09 (1.04–1.14)\*\*\* | 1.08 (1.03–1.12)\*\* |
|  | Imipramine | 36,367 | 2,489 | 377,730 | 6.6 | 1.30 (1.23–1.37)\*\*\* | 1.13 (1.07–1.19)\*\*\* | 1.08 (1.02–1.14)\*\* | 1.06 (1.00–1.12) |
| MAOI | |  |  |  |  |  |  |  |  |
|  | Selegiline | 316 | 30 | 3,355 | 8.9 | 1.76 (1.23–2.53)\*\* | 0.79 (0.55–1.13) | 0.78 (0.54–1.12) | 0.80 (0.56–1.16) |
| Others | |  |  |  |  |  |  |  |  |
|  | Mirtazapine | 18,590 | 1,018 | 173,939 | 5.9 | 1.18 (1.10–1.26)\*\*\* | 0.93 (0.86–1.00)\* | 0.93 (0.86–1.00) | 0.87 (0.81–0.94)\*\*\* |
|  | Bupropion | 14,203 | 458 | 110,474 | 4.1 | 0.87 (0.79–0.97)\*\* | 0.87 (0.79–0.96)\*\* | 0.87 (0.79–0.96)\*\* | 0.85 (0.77–0.95)\*\* |
|  | Trazodone | 67,548 | 3,282 | 580,751 | 5.7 | 1.15 (1.09–1.21)\*\*\* | 1.00 (0.95–1.05) | 0.96 (0.91–1.01) | 0.90 (0.85–0.95)\*\*\* |
|  | Vortioxetine | 7,697 | 57 | 41,852 | 1.4 | 0.29 (0.22–0.37)\*\*\* | 0.27 (0.21–0.35)\*\*\* | 0.27 (0.21–0.35)\*\*\* | 0.27 (0.21–0.35)\*\*\* |

DEP, depression; SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; MAOI, monoamine oxidase inhibitor

**a**Adjusted for age (years) and sex

**b**Adjusted for age (years), sex, and Charlson comorbidity Index

**c**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, and zolpidem use

\**P* <0.05, \*\**P* <0.01, \*\*\**P* <0.001

**Supplementary Table 5. Hazard ratios and 95% confidence intervals of antidepressant combinations on type 2 diabetes compared to healthy controls**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Subjects**  **(n)** | **Events (n)** | **Follow-up duration (person-year)** | **Incidence rate**  **(per 1000 person-years)** | **Hazard ratio (95% Confidence interval)** | | | |
| **Crude** | **Model 1a** | **Model 2b** | **Model 3c** |
| Healthy controls | 276,048 | 24,577 | 3,954,318 | 6.2 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| SSRI only | 70,108 | 2,117 | 455,491 | 4.6 | 0.85 (0.81–0.89)\*\*\* | 1.07 (1.02–1.12)\*\* | 1.02 (0.97–1.07) | 0.86 (0.81–0.90)\*\*\* |
| TCA only | 48,754 | 5,098 | 439,207 | 11.6 | 2.04 (1.98–2.11)\*\*\* | 1.61 (1.56–1.66)\*\*\* | 1.41 (1.37–1.46)\*\*\* | 1.25 (1.20–1.30)\*\*\* |
| SSRI+TCA | 41,358 | 2,275 | 413,002 | 5.5 | 0.97 (0.93–1.01) | 0.89 (0.85–0.93)\*\*\* | 0.77 (0.74–0.81)\*\*\* | 0.66 (0.63–0.70)\*\*\* |
| Other combinations | 115,828 | 5,370 | 975,963 | 5.5 | 0.97 (0.95–1.00) | 0.85 (0.82–0.87)\*\*\* | 0.73 (0.71–0.75)\*\*\* | 0.60 (0.58–0.63)\*\*\* |

SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressant

**a**Adjusted for age (years) and sex

**b**Adjusted for age (years), sex, and Charlson comorbidity Index

**c**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, and zolpidem use

\**P* <0.05, \*\**P* <0.01, \*\*\**P* <0.001

**Supplementary Table 6. Hazard ratios and 95% confidence intervals of antidepressant combinations on type 2 diabetes compared to DEP without antidepressants group.**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Subjects**  **(n)** | **Events (n)** | **Follow-up duration (person-year)** | **Incidence rate**  **(per 1000 person-years)** | **Hazard ratio (95% Confidence interval)** | | | |
| **Crude** | **Model 1a** | **Model 2b** | **Model 3c** |
| DEP without antidepressants | 79,119 | 2,898 | 603,168 | 4.8 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| SSRI only | 70,108 | 2,117 | 455,491 | 4.6 | 1.01 (0.95–1.06) | 1.19 (1.12–1.26)\*\*\* | 1.17 (1.11–1.24)\*\*\* | 1.14 (1.07–1.20)\*\*\* |
| TCA only | 48,754 | 5,098 | 439,207 | 11.6 | 2.37 (2.26–2.48)\*\*\* | 1.88 (1.80–1.97)\*\*\* | 1.74 (1.66–1.82)\*\*\* | 1.75 (1.67–1.84)\*\*\* |
| SSRI+TCA | 41,358 | 2,275 | 413,002 | 5.5 | 1.12 (1.06–1.18)\*\*\* | 1.01 (0.96–1.07) | 0.92 (0.87–0.97)\*\* | 0.91 (0.86–0.96)\*\*\* |
| Other combinations | 115,828 | 5,370 | 975,963 | 5.5 | 1.13 (1.08–1.18)\*\*\* | 0.97 (0.93–1.02) | 0.88 (0.84–0.92)\*\*\* | 0.83 (0.79–0.87)\*\*\* |

DEP, depression; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressant

**a**Adjusted for age (years) and sex

**b**Adjusted for age (years), sex, and Charlson comorbidity Index

**c**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, and zolpidem use

\**P* <0.05, \*\**P* <0.01, \*\*\**P* <0.001

**Supplementary Table 7. Hazard ratios and 95% confidence intervals on type 2 diabetes among the depression patients with diagnostic codes including symptom severity**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Subjects**  **(N)** | **Events (N)** | **Follow-up duration (person-year)** | **Incidence rate**  **(Per 1000 person-years)** | **Hazard ratio**  **(95% Confidence interval)** | | | | |
| **Crude** | **Model 1a** | **Model 2b** | **Model 3c** | **Model 4d** |
| Group | |  |  |  |  |  |  |  |  |  |
|  | Healthy controls | 276,048 | 24,577 | 3,954,318 | 6.2 | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
|  | DEP with antidepressantse | 144,538 | 6,599 | 1,150,379 | 5.7 | 1.03 (1.00–1.05) | 1.02 (0.99–1.04) | 0.92 (0.89–0.95)\*\*\* | 0.83 (0.79–0.86)\*\*\* | 0.81 (0.77–0.85)\*\*\* |
|  | DEP without antidepressantsf | 38,777 | 1,298 | 293,745 | 4.4 | 0.79 (0.75–0.84)\*\*\* | 0.85 (0.81–0.90)\*\*\* | 0.82 (0.78–0.87)\*\*\* | 0.75 (0.71–0.80)\*\*\* | 0.74 (0.69–0.79)\*\*\* |
| Symptom severity | |  |  |  |  |  |  |  |  |  |
|  | Mild | 86,093 | 3,804 | 682,709 | 5.6 | 1 (Ref.) |  |  |  | 1 (Ref.) |
|  | Moderate | 72,925 | 3,018 | 573,398 | 5.3 | 0.95 (0.90–0.99)\* |  |  |  | 1.05 (1.00–1.10)\* |
|  | Severe | 24,297 | 1,075 | 188,017 | 5.7 | 1.03 (0.96–1.10) |  |  |  | 1.03 (0.96–1.11) |

DEP = depression.

**a**Adjusted for age (years) and sex.

**b**Adjusted for age (years), sex, and Charlson comorbidity Index.

**c**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, and zolpidem use.

**d**Adjusted for age (years), sex, Charlson comorbidity index, income, disability, personality disorders, antipsychotic use, benzodiazepine use, stimulant use, mood stabilizer use, zolpidem use, and symptom severity

eSubjects who had been diagnosed with depression and prescribed antidepressants.

fSubjects who had been diagnosed with depression but not prescribed antidepressants.

\**P* <0.05, \*\**P* <0.01, \*\*\**P* <0.001